Key Stats:
Avalon Pharmaceuticals, Inc.
20358 Seneca Meadows Parkway
Germantown, MD 20876
Phone: 301-556-9900
Fax: 301-556-9910
Web Site: avalonrx.com
Of the 2.75 million from the dutch auction IPO, it appears that Insiders purchased almost 1 million of those.
WALTON ALAN G Director
10% owner 181,400 $10.5 $1,904,700.00 673,261
Whitaker Raymond J Director 203,900 $10.5 $2,140,950.00 203,900
ROYSTON IVOR Director 136,000 $10.5 $1,428,000.00 136,000
ADVIESBEHEER GIMV LIFE SCIENCES NV 10% owner 181,400 $10.5 $1,904,700.00 181,400
Beneden Patrick Van Director
10% owner 181,400 $10.5 $1,904,700.00 181,400
From The Deal.com
As of the offering, the Germantown, Md.-based company has a market capitalization of approximately $92.3 million.
The biopharmaceuticals company's $80 million in venture financing came primarily through a $70 million second round in December 2001. Toronto's CDP Sofinov led that round with an $8 million investment. U.K.-based EuclidSR Partners; France's AIG Global Investment Group; Hambrecht & Quist Capital Management LLC of San Francisco; MDS Capital Corp. and RBC Capital Partners, both of Toronto; Montreal's GeneChem Mnagement Inc.; and OrbiMed Advisors LLC and KBL Healthcare Ventures, both of New York, also came in as new investors.
Previous investors Oxford Bioscience Partners, GIMV NV, Forward Ventures, Emerging Technology Partners LLC and Maryland Department of Business and Economic Development also came back to build on a $10 million first round from June 2000.
AVALON's largest shareholder is GIMV, which owns 12.2% of the company. |
